Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STEGLATRO vs FARXIGA
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Steglatro (ertugliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose.
Selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFr EF) (off-label)
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Reduce risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors,Reduce risk of sustained e GFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression
0.5 mg orally once daily for patients with type 2 diabetes; no dose adjustment for age, gender, or race.
10 mg orally once daily, with or without food.
Terminal elimination half-life is approximately 12.4 hours in patients with type 2 diabetes, supporting once-daily dosing. No accumulation occurs at steady state.
Terminal elimination half-life 12-13 hours; supports once-daily dosing. Steady-state reached in 5 days.
Ertugliflozin is primarily metabolized via glucuronidation by UGT1A9 and UGT2B7 to two inactive glucuronide metabolites. Minor metabolism via CYP3A4 and CYP2C8.
e GFR ≥ 60 m L/min/1.73 m²: no dose adjustment. e GFR 30 to < 60: not recommended due to lack of efficacy. e GFR < 30: contraindicated.
e GFR >= 45 m L/min/1.73 m²: no adjustment; e GFR 25-44 m L/min/1.73 m²: not recommended for glycemic control, may be used for heart failure and chronic kidney disease; e GFR < 25 m L/min/1.73 m²: contraindicated for glycemic control, not recommended for heart failure or chronic kidney disease.
None
Pregnancy Category C: No adequate studies in pregnant women. In animal studies, fetal skeletal variations and reduced fetal weight were observed at exposures ≥1.8 times the human exposure at maximum recommended human dose. Use only if potential benefit justifies potential risk.
Dapagliflozin is not recommended during the second and third trimesters due to potential fetal renal toxicity. Limited human data in the first trimester; animal studies show fetal toxicity at high doses. Avoid use in pregnant women.
STEGLATRO (ertugliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Monitor for genital mycotic infections, especially in uncircumcised males. Can cause volume depletion; assess renal function (e GFR) before initiation and periodically. Contraindicated if e GFR <30 m L/min/1.73m². May increase LDL-C. Rare risk of Fournier gangrene (necrotizing fasciitis of perineum).
Farxiga (dapagliflozin) is an SGLT2 inhibitor indicated for type 2 diabetes, HFr EF, and CKD. Monitor for euglycemic DKA (normal glucose but ketosis), genital mycotic infections, and volume depletion (especially with loop diuretics). Can cause acute kidney injury if e GFR declines; hold before surgery or prolonged fasting. May lower uric acid and blood pressure. Contraindicated in type 1 diabetes and history of diabetic ketoacidosis.
No interactions on record
No interactions on record
STEGLATRO and FARXIGA are distinct pharmacological agents. STEGLATRO belongs to the SGLT2 Inhibitor class and is primarily used for Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitusTo reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF) (off-label). FARXIGA belongs to the SGLT2 Inhibitor class and is primarily used for Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitusReduce risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factorsReduce risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. STEGLATRO carries a safety status of Category C, whereas FARXIGA safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily metabolized via UGT1A9 and UGT2B7 glucuronidation; minor CYP metabolism (CYP3A4).
Approximately 65% of the dose is excreted in the urine as unchanged drug via active tubular secretion, and 35% is excreted in the feces as unchanged drug, indicating minimal metabolism.
Renal (33% as parent, 66% as glucuronide conjugates in urine); fecal (1.5% as parent); biliary (minor).
Approximately 95% bound to plasma proteins, primarily serum albumin.
91%; primarily to serum albumin.
Mean apparent volume of distribution at steady state is 1.8 L/kg, indicating extensive extravascular distribution.
~72 L (not L/kg, absolute Vd ~72 L); extensive distribution into extravascular tissues.
Oral bioavailability is approximately 75% under fasted conditions. Absorption is not significantly affected by food, so it can be taken with or without meals.
78% after oral administration (fasted); high fat meal decreases Cmax and AUC by 30-50% but no significant clinical effect.
Child-Pugh Class A (mild): no dose adjustment. Child-Pugh Class B (moderate): not recommended. Child-Pugh Class C (severe): contraindicated.
Mild to moderate hepatic impairment (Child-Pugh A and B): no dose adjustment; severe hepatic impairment (Child-Pugh C): not recommended.
Safety and efficacy not established in pediatric patients under 18 years.
Not indicated for pediatric patients below 18 years of age; safety and efficacy not established.
No dose adjustment required based solely on age. Consider renal function and risk of volume depletion.
No dose adjustment required based on age; consider renal function and risk of volume depletion, especially in patients >= 75 years.
None.
No specific food interactions. Alcohol may increase risk of dehydration and ketoacidosis.
No significant food interactions; can be taken with or without meals. Avoid excessive alcohol intake as it may increase risk of ketoacidosis.
No data on presence in human milk, effects on breastfed infant, or effects on milk production. Excreted in rat milk at concentrations 0.5-1.5 times maternal plasma. Due to potential for serious adverse reactions, advise against breastfeeding during treatment and for 2 weeks after last dose.
Dapagliflozin is excreted in animal milk; unknown in human milk. M/P ratio not established. Discontinue breastfeeding due to potential risk to the infant.
No specific dose adjustments established due to lack of pharmacokinetic data in pregnancy. Physiological changes in pregnancy (e.g., increased plasma volume, renal clearance) may reduce drug exposure; monitor clinical response and adjust dose if necessary based on efficacy and tolerability.
No dose adjustment recommended for pregnancy because the drug is contraindicated. Pharmacokinetic changes in pregnancy do not apply.
Take once daily with or without food.,Drink plenty of fluids to prevent dehydration.,Report symptoms of urinary tract infections or genital itching/discharge.,Seek immediate medical attention for pain, tenderness, redness, or swelling in the genital or rectal area.,May cause dizziness upon standing; rise slowly from sitting or lying position.,Do not use if you have severe kidney disease or are on dialysis.
Take once daily, with or without food, preferably in the morning.,Drink plenty of fluids to prevent dehydration; report symptoms like dizziness or fainting.,Watch for signs of genital yeast infections (itching, discharge) or urinary tract infections (painful urination).,Seek medical attention immediately if you experience unusual fatigue, nausea, vomiting, or difficulty breathing (signs of ketoacidosis even if blood sugar is normal).,Do not use if you have type 1 diabetes or a history of diabetic ketoacidosis.,Inform your doctor before any surgery or prolonged fasting as doses may need adjustment.